CHMP recommends SC Rybrevant for EGFR-mutated NSCLC patients
3rd February 2025 Uncategorised 0
Positive opinion issued for marketing authorisation extension
More: CHMP recommends SC Rybrevant for EGFR-mutated NSCLC patients
Source: News
Positive opinion issued for marketing authorisation extension
More: CHMP recommends SC Rybrevant for EGFR-mutated NSCLC patients
Source: News
© 1994 - 2025 B.M. Pharmaceuticals